Production and purification of recombinant adeno-associated vectors.
The use of recombinant adeno-associated virus (rAAV) vectors in gene therapy for preclinical studies in animal models and human clinical trials is increasing, as these vectors have been shown to be safe and to mediate persistent transgene expression in vivo. Constant improvement in rAAV manufacturing processes (upstream production and downstream purification) has paralleled this evolution to meet the needs for larger vector batches, higher vector titer, and improved vector quality and safety. This chapter provides an overview of existing production and purification systems used for adeno-associated virus (AAV) vectors, and the advantages and disadvantages of each system are outlined. Regulatory guidelines that apply to the use of these systems for clinical trials are also presented. The methods described are examples of protocols that have been utilized for establishing rAAV packaging cell lines, production of rAAV vectors using recombinant HSV infection, and for chromatographic purification of various AAV vector serotypes. A protocol for the production of clinical-grade rAAV type 2 vectors using transient transfection and centrifugation-based purification is also described.
Center of Excellence for Regenerative Health Biotechnology, University of Florida, Alachua, FL, USA.
Lijun
L
Wang
Véronique
V
Blouin
Nicole
N
Brument
Mahajoub
M
Bello-Roufai
Achille
A
Francois
D000818:Animals; D000229:Dependovirus / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000096:biosynthesis* / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans